Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18558988 | 0.79 | — | — | |
| SCHEMBL18238082 | 0.76 | METAP2 (0.37) | METAP2IDO1NOS1AXL | |
| SCHEMBL17705710 | 0.67 | ADORA3 (0.31) | — | |
| SCHEMBL16276755 | 0.67 | HTT (0.40) | METAP2IDO1HTTPTK2NOS1 | |
| SCHEMBL16339751 | 0.67 | IDO1 (0.41) | METAP2IDO1NOS1AXL | |
| SCHEMBL12258192 | 0.67 | HSP90AA1 (0.41) | METAP2IDO1HTTPTK2NOS1 | |
| SCHEMBL17705707 | 0.66 | GPR84 (0.33) | — | |
| SCHEMBL24981147 | 0.64 | HTT (0.38) | METAP2IDO1HTTPTK2ALDH1A1 | |
| SCHEMBL2611044 | 0.64 | RET (0.55) | ALDH1A1 | |
| SCHEMBL11605459 | 0.64 | MAPT (0.38) | METAP2IDO1HTTPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579319-B2 | Heterocyclic compounds as hedgehog signaling pathway inhibitors | REDX PHARMA PLC (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9579319-B2 | Heterocyclic compounds as hedgehog signaling pathway inhibitors | REDX PHARMA PLC (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160113928-A1 | HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113928-A1 | HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS | SMO, SHH, GLI1 | METAP2 3733/4885IDO1 1352/4885HTT 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.